Cabometyx (cabozantinib)

pCPA File Number: 22062

Negotiation Status:

Under consideration for negotiation

Indication(s):

Treatment of adult patients with differentiated thyroid carcinoma (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are radioactive iodine-refractory (RAI-R) or ineligible

Sponsor/Manufacturer:

Ipsen Biopharmaceuticals

CADTH Project Number:

PC0287

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable